GlassScriptPhysician profile
Alan S Kricsfeld
NPI 1467406017
$48,833.10
in general payments reported to CMS, 2019-2025
54 companies · $3,336 in 2025
The $3,336 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $6,053 · 2021: $3,239 · 2022: $5,183 · 2023: $3,745 · 2024: $3,376 · 2025: $3,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,318.41 |
| Education | $138.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $24,877.97 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $3,232.56 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $2,370.63 | 2021-2025 | |
| Abbvie INC. | $1,630.08 | 2021-2025 | |
| Amgen INC. | $1,621.08 | 2019-2025 | Repatha, Evenity, Prolia |
| Gilead Sciences, INC. | $1,298.10 | 2019-2025 | Epclusa |
| Novo Nordisk INC | $1,145.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $1,076.84 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,040.77 | 2019-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $874.91 | 2021-2024 | Linq II, Azure Xt Dr Mri Surescan |
| Lilly USA, LLC | $838.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $729.63 | 2020-2025 | Nexletol |
| Glaxosmithkline, LLC. | $676.60 | 2021-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Medtronic Vascular, INC. | $650.58 | 2019-2020 | |
| Axsome Therapeutics, INC. | $622.52 | 2024-2025 | Auvelity |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Kricsfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.